Select Publications
Journal articles
2019, 'Estrogen receptor signaling is reprogrammed during breast tumorigenesis', Proceedings of the National Academy of Sciences of the United States of America, 166, pp. 11437 - 11443, http://dx.doi.org/10.1073/pnas.1819155116
,2019, 'Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer', Endocrine-Related Cancer, 26, pp. R15 - R30, http://dx.doi.org/10.1530/ERC-18-0317
,2019, 'The IAC Yokohama system for reporting breast FNAB cytology', Acta Cytologica, 63, pp. 257 - 273, http://dx.doi.org/10.1159/000499509
,2019, 'The proliferative and apoptotic landscape of basal-like breast cancer', International Journal of Molecular Sciences, 20, http://dx.doi.org/10.3390/ijms20030667
,2018, 'A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-04619-5
,2018, 'Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer', Nature Communications, 9, pp. 2897, http://dx.doi.org/10.1038/s41467-018-05220-6
,2018, 'Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial', The Lancet Oncology, 19, pp. 1385 - 1393, http://dx.doi.org/10.1016/S1470-2045(18)30380-2
,2018, 'Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer', Asia-Pacific Journal of Clinical Oncology, 14, pp. 12 - 21, http://dx.doi.org/10.1111/ajco.13065
,2018, 'Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm', Asia-Pacific Journal of Clinical Oncology, 14, pp. 3 - 11, http://dx.doi.org/10.1111/ajco.13064
,2018, 'Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia', Clinical Endocrinology, 89, pp. 280 - 296, http://dx.doi.org/10.1111/cen.13735
,2018, 'Attitudes of patients with metastatic cancer towards research biopsies', Asia-Pacific Journal of Clinical Oncology, 14, pp. 231 - 238, http://dx.doi.org/10.1111/ajco.12783
,2018, 'Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling', Nature Medicine, 24, pp. 463 - 473, http://dx.doi.org/10.1038/nm.4494
,2018, 'Erratum: Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells (eLife (2014) 3 (e01763) PII: e36414)', eLife, 7, http://dx.doi.org/10.7554/eLife.36414
,2018, 'Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy', EBioMedicine, 29, pp. 166 - 176, http://dx.doi.org/10.1016/j.ebiom.2018.01.041
,2017, 'Endocrine therapy for breast cancer: A Renaissance', The Endocrinologist, pp. 13 - 14
,2017, 'Secreted Tumor Antigens – Immune Biomarkers for Diagnosis and Therapy', Proteomics, 17, http://dx.doi.org/10.1002/pmic.201600442
,2017, 'Sensitizing HR-proficient cancers to PARP inhibitors', Molecular and Cellular Oncology, 4, http://dx.doi.org/10.1080/23723556.2017.1299272
,2017, 'Neoadjuvant interferons: Critical for effective PD-1–based immunotherapy in TNBC', Cancer Immunology Research, 5, pp. 871 - 884, http://dx.doi.org/10.1158/2326-6066.CIR-17-0150
,2017, 'Erratum: The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy (Endocrine-related cancer (2017) 24 4 (R123-R144) PII: ERC160404e)', Endocrine-related cancer, 24, pp. X1, http://dx.doi.org/10.1530/ERC-16-0404e
,2017, 'The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy', Endocrine-Related Cancer, 24, pp. R123 - R144, http://dx.doi.org/10.1530/ERC-16-0404
,2017, 'Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer', Cell Reports, 18, pp. 2359 - 2372, http://dx.doi.org/10.1016/j.celrep.2017.02.025
,2017, 'The role of MDM2 and MDM4 in breast cancer development and prevention', Journal of molecular cell biology, 9, pp. 53 - 61, http://dx.doi.org/10.1093/jmcb/mjx007
,2017, 'PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer', Annals of Oncology, 28, pp. v107 - v108, http://dx.doi.org/10.1093/annonc/mdx365.087
,2016, 'EMT, cell plasticity and metastasis', Cancer and Metastasis Reviews, 35, pp. 645 - 654, http://dx.doi.org/10.1007/s10555-016-9648-7
,2016, 'Pushing estrogen receptor around in breast cancer', Endocrine-Related Cancer, 23, pp. T227 - T241, http://dx.doi.org/10.1530/ERC-16-0427
,2016, 'CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer', Cell Reports, 17, pp. 2367 - 2381, http://dx.doi.org/10.1016/j.celrep.2016.10.077
,2016, 'Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: how should the skeletal and vascular side effects be assessed and managed?', Clinical Endocrinology, 85, pp. 689 - 693, http://dx.doi.org/10.1111/cen.13172
,2016, 'Renewed interest in the progesterone receptor in breast cancer', British Journal of Cancer, 115, pp. 909 - 911, http://dx.doi.org/10.1038/bjc.2016.303
,2016, 'IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG', Oncogene, 35, pp. 1111 - 1121, http://dx.doi.org/10.1038/onc.2015.164
,2016, 'Clinical overview of MDM2/X-targeted therapies', Frontiers in Oncology, 6, http://dx.doi.org/10.3389/fonc.2016.00007
,2016, 'MECP2 is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy', Cancer Discovery, 6, pp. 45 - 58, http://dx.doi.org/10.1158/2159-8290.CD-15-0341
,2015, 'Erratum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel (Nature Communications (2015) 6 (8746) DOI: 10.1038/ncomms9746)', Nature Communications, 6, http://dx.doi.org/10.1038/ncomms10054
,2015, 'IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel', Nature Communications, 6, http://dx.doi.org/10.1038/ncomms9746
,2015, 'CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer', Cell, 163, pp. 174 - 186, http://dx.doi.org/10.1016/j.cell.2015.08.063
,2015, 'Targeting the Androgen Receptor in Breast Cancer', Current Oncology Reports, 17, http://dx.doi.org/10.1007/s11912-014-0427-8
,2015, 'A laminin 511 matrix is regulated by Taz and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells', Genes and Development, 29, pp. 1 - 6, http://dx.doi.org/10.1101/gad.253682.114
,2014, 'PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination–mediated DNA repair', Cancer Discovery, 4, pp. 1430 - 1447, http://dx.doi.org/10.1158/2159-8290.CD-13-0891
,2014, 'Phosphorylation of ETS1 by src family kinases prevents its recognition by the COP1 tumor suppressor', Cancer Cell, 26, pp. 222 - 234, http://dx.doi.org/10.1016/j.ccr.2014.06.026
,2014, 'Updates on the management of breast cancer brain metastases', Oncology (Williston Park), 28, pp. 572 - 578
,2014, 'MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells', eLife, 2014, http://dx.doi.org/10.7554/eLife.01763
,2014, 'Importance of breast cancer subtype in the development of androgen-receptor-directed therapy', Current Breast Cancer Reports, 6, pp. 71 - 78, http://dx.doi.org/10.1007/s12609-014-0140-5
,2014, 'XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway', Nature, 508, pp. 103 - 107, http://dx.doi.org/10.1038/nature13119
,2013, 'Protein Kinase C α Is a Central Signaling Node and Therapeutic Target for Breast Cancer Stem Cells', Cancer Cell, 24, pp. 347 - 364, http://dx.doi.org/10.1016/j.ccr.2013.08.005
,2013, 'The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor', Cancer Cell, 24, pp. 365 - 378, http://dx.doi.org/10.1016/j.ccr.2013.08.004
,2013, 'Breast cancer in adolescents and young adults: A review with a focus on biology', JNCCN Journal of the National Comprehensive Cancer Network, 11, pp. 1060 - 1069, http://dx.doi.org/10.6004/jnccn.2013.0128
,2013, 'PDEF Promotes Luminal Differentiation and Acts as a Survival Factor for ER-Positive Breast Cancer Cells', Cancer Cell, 23, pp. 753 - 767, http://dx.doi.org/10.1016/j.ccr.2013.04.026
,2013, 'Amplitude modulation of androgen signaling by c-MYC', Genes and Development, 27, pp. 734 - 748, http://dx.doi.org/10.1101/gad.209569.112
,2012, 'Abstract PD01-08: Differences in estrogen receptor signaling in non-malignant primary ER-positive breast epithelial cells and breast cancer.', Cancer Research, 72, http://dx.doi.org/10.1158/0008-5472.sabcs12-pd01-08
,2012, 'IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation', Molecular and Cellular Biology, 32, pp. 4756 - 4768, http://dx.doi.org/10.1128/MCB.00468-12
,2012, 'Elucidating the role of androgen receptors and breast cancer.', Clinical Investigation, 2, pp. 1003 - 1011
,